Current Report Filing (8-k)
May 15 2017 - 7:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (date of earliest event
reported): May 15, 2017
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified
in its charter)
Nevada
|
001-36019
|
26-1434750
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
509 Madison Avenue, Suite 306, New York,
New York 10022
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number,
including area code:
(212) 980-9155
Copy of correspondence to:
Marc J. Ross, Esq.
James M. Turner, Esq.
Sichenzia Ross Ference Kesner LLP
61 Broadway
New York, New York 10006
Tel: (212) 930-9700 Fax: (212) 930-9725
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company
¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On May 15, 2017, Tonix Pharmaceuticals
Holding Corp. (the “Company”) announced its operating results for the first fiscal quarter ended March 31, 2017. A
copy of the press release that discusses this matter is filed as Exhibit 99.01 to, and incorporated by reference in, this report.
The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act
of 1933, except as shall be expressly set forth by specific reference in any such filing.
|
Item 7.01
|
Regulation FD Disclosure.
|
The Company intends to utilize an updated
investor presentation to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the
Company intends to place on its website, which may contain non-public information. A copy of the presentation is filed
as Exhibit 99.02.
The information contained in Item 7.01
of this Current Report on Form 8-K, including Exhibit 99.02, is furnished pursuant to, and shall not be deemed to be "filed"
for the purposes of, Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section. The information contained in Item 7.01 of this Current Report shall not be incorporated by reference into
any registration statement or any other document filed pursuant to the Securities Act of 1933, as amended, except as otherwise
expressly stated in such filing. By filing this Current Report on Form 8-K and furnishing the information contained
in this Item 7.01, including Exhibit 99.02, the Company makes no admission as to the materiality of any such information that it
is furnishing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
* Furnished herewith.
SIGNATURE
Pursuant to the requirement
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
TONIX PHARMACEUTICALS HOLDING CORP.
|
|
|
|
Date: May 15, 2017
|
|
By:
|
/s/ BRADLEY SAENGER
|
|
|
Bradley Saenger
|
|
|
Chief Financial Officer
|
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024